With so much time and resources being spent addressing daily challenges, sponsors often lack the resources and technology to pursue enterprise-level strategies for planning future clinical trials. In this post, we list some of the key strategic imperatives for biomarker and clinical operations teams, and how can they be addressed by creating wide visibility across vendor and site performance.
Duration: 30 minutes Register to Watch On Demand: Summary Clinical and translational teams must monitor biomarker samples across global site footprints and dispersed networks of labs and biorepositories. It’s easy to get bogged down by managing the day-to-day requirements of keeping studies on track. With samples as the critical first step toward data generation, modern […]
The clinical and biomarker operations teams at a mid-sized oncology biotech client depend on QuartzBio’s Sample Intelligence solution to gain global visibility into their biomarker operations. Teams can monitor vendor performance within and across studies, an increasingly critical success factor with increased collections and complex sample routing.
With immuno-oncology assets progressing in the clinic, a growing biotechnology company we work with faces an increasingly common challenge: Their trials are generating large datasets across a wide range of assay modalities (Figure 1), but the data remains siloed. In addition to clinical data coming from the clinical research organization (CRO), the velocity of data […]
October 8, 2021 — Sponsors are challenged to keep track of complex sample inventories, both on study and for samples collected as part of completed studies that might be later mined for translational research needs. We frequently hear that teams spend significant time manually cross-referencing spreadsheets of inventory data, to answer questions such as: “How […]
Clinical samples are moving across an increasing number of physical/virtual locations and data is delivered in an expanding array of file formats as clinical trials become increasingly more complex and data-rich (report). Biospecimens are analyzed using a variety of assay technologies, each generating its own set of reportables, quality control metrics and data/file formats. Data […]
For recent protocols, biospecimen collections are designed to be broad and to enable flexible selection from the variety of biomarker assay technologies that are available. Biomarker clinical operations are critical to realizing the potential of biomarker data generation plans. In this post, we explore the relationship between “lab-centric” and “sponsor-centric” sample inventory reporting, and how connecting these inventories can keep data generation on track.
May 5, 2021 — As the data generated during a modern clinical trial has dramatically expanded, sponsors must continuously evaluate novel approaches to help bridge the gap between millions of data points and breakthrough scientific insights (a goal we describe as delivering Translational Intelligence). One such example is assessing signatures of “hot” and “cold” tumors.
April 21, 2021 — A modern clinical trial, with well-characterized subjects studied over periods of time, presents unmissable opportunities for sponsors to characterize mechanism of action, prioritize target pathways for their pipelines, and generate as much data as possible to support regulatory filings.
Watch on Demand: Integrating Data Silos to Unlock Scientific Insights and Empower Translational Teams Duration: 45 minutes Sign up to watch the webinar on demand: You will learn how to: Abstract of the Webinar Today’s clinical trials have global footprints to reach targeted patient populations and rely on specialty labs running complex assays to assess safety, […]
QuartzBio is the only company purpose-built to deliver end-to-end Sample and Biomarker Intelligence for clinical-stage biopharma teams. Powered by a network of domain-specific AI agents, our solutions transform fragmented data into actionable intelligence, enabling conversational insights into your unified ecosystem of sample, clinical, and biomarker data.
QUARTZBIO® is a registered trademark of Precision Regulatory and Translational Sciences, Inc., dba QuartzBio, in the United States and/or other jurisdictions. All rights reserved.
© 2026 QuartzBio.
All rights reserved.
Privacy Policy | GDPR
